This increase in CX3CR1 levels is associated with anti-tumor responses triggered by OncoTherad® (MRB-CFI-1) therapy applied to BCG-unresponsive patients with carcinoma in situ. The gene discussed is CX3CR1; the disease is in situ carcinoma.